SI-BONE, Inc. is a medical device company, which engages in the provision of a proprietary minimally invasive surgical implant system to fuse the sacroiliac joint for treatment of musculoskeletal disorders of the sacropelvic anatomy. The company is headquartered in Santa Clara, California and currently employs 349 full-time employees. The company went IPO on 2018-10-17. The firm specializes in minimally invasive surgical implant systems to address sacroiliac joint dysfunction as well as address unmet clinical needs in pelvic fixation and management of pelvic fractures. The firm's products include a series of patented titanium implants, and the instruments used to implant them, as well as implantable bone products. Its products include iFuse, iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite. Within the United States, iFuse, iFuse-3D and iFuse-TORQ have clearances for applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma. Its first-generation iFuse, a machined triangular titanium implant, has a triangular cross section that resists twisting or rotation of the implant. The firm's second generation iFuse product, the iFuse-3D implant, is a patented titanium implant.
Follow-Up Questions
SI-BONE Inc의 CEO는 누구입니까?
Ms. Laura Francis은 2015부터 회사에 합류한 SI-BONE Inc의 Chief Executive Officer입니다.
SIBN 주식의 가격 성능은 어떻습니까?
SIBN의 현재 가격은 $14.74이며, 전 거래일에 decreased 0% 하였습니다.
SI-BONE Inc의 주요 사업 주제나 업종은 무엇입니까?
SI-BONE Inc은 Health Care 업종에 속하며, 해당 부문은 Health Care입니다
SI-BONE Inc의 시가총액은 얼마입니까?
SI-BONE Inc의 현재 시가총액은 $635.8M입니다
SI-BONE Inc는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 11명의 분석가가 SI-BONE Inc에 대한 분석 평가를 실시했으며, 이는 4명의 강력한 매수, 10명의 매수, 1명의 보유, 0명의 매도, 그리고 4명의 강력한 매도를 포함합니다